What safety risks are associated with Xgeva (denosumab)?
Xgeva (denosumab) safety concerns most often center on how it affects bone turnover and mineral levels. Reported important risks include low calcium in the blood (hypocalcemia), serious infections in some patients, osteonecrosis of the jaw (ONJ), atypical femur fractures, and other complications related to long-term suppression of bone remodeling. These risks and monitoring requirements are reflected in Xgeva’s prescribing information and safety communications [1].
How common is hypocalcemia, and who is at highest risk?
Hypocalcemia is a key safety issue for denosumab. Risk is higher in people with impaired kidney function and in those who do not receive adequate calcium and vitamin D supplementation. Patients are typically instructed to take calcium and vitamin D and to have calcium checked before and during treatment when clinically appropriate [1]. In settings where patients have extensive bone involvement, clinicians also watch closely because serum calcium can drop further as denosumab suppresses bone resorption [1].
What is osteonecrosis of the jaw (ONJ) with Xgeva, and what should patients do?
ONJ is a well-recognized complication of antiresorptive therapies like denosumab. It can present as exposed jaw bone, pain, swelling, infection, or non-healing sores. Patients are advised to maintain good oral hygiene, have dental issues evaluated early, and alert their oncologist or dentist if they develop mouth pain, swelling, or non-healing lesions during treatment [1].
What is an atypical femur fracture, and what symptoms should be watched for?
With long-term use of drugs that suppress bone turnover, atypical femur fractures can occur. Patients are advised to report new or unusual thigh, hip, or groin pain, since such symptoms may precede a fracture and prompt evaluation [1].
Can Xgeva cause infections or affect the immune system?
Serious infections have been reported with denosumab. Clinicians evaluate infection risk factors and monitor patients who develop signs of infection while on therapy [1].
How is Xgeva administered, and how does that affect safety monitoring?
Xgeva is given as an injection according to the dosing schedule in the prescribing information, and safety monitoring is built around the major risks above—especially calcium levels and dental/ONJ precautions [1]. Your treating clinician may check labs and adjust supportive care (like calcium/vitamin D) based on baseline risk factors and ongoing results [1].
What drug or condition factors increase risk?
Safety risk can increase with factors that predispose to low calcium (such as kidney impairment) and with conditions that raise ONJ risk (such as poor oral health or invasive dental procedures). The prescribing information highlights risk factors and the need for supportive measures and monitoring [1].
Are there alternatives to Xgeva if safety concerns come up?
Alternative bone-protective options may be considered depending on the cancer setting and patient risk profile, but the right choice depends on the specific diagnosis and overall treatment plan. Safety decisions generally weigh hypocalcemia risk, ONJ risk, kidney function, and how each option fits with the patient’s cancer therapy [1].
What should you do if you suspect a serious side effect?
For symptoms consistent with hypocalcemia (such as muscle cramps or spasms, tingling around the mouth), ONJ (jaw pain, swelling, exposed bone, non-healing mouth sores), or possible atypical fracture (new thigh/hip/groin pain), patients should contact their oncology team promptly. Serious or worsening symptoms should be evaluated urgently [1].
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/